Charles River Laboratories International, Inc. CRL
i
Market dataready · fetched 2026-11-11T14:03:38.471Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T09:03:15.168170773Z
FundamentalsSEC EDGAR · ready · as of 2026-09-26 · fetched 2026-11-11T14:03:38.038822+00:00
Charles River Laboratories International, Inc. options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 376.79 | 60.3% | 10.0% | 320.66 | 61.1% | 8.4% |
| 25Δ | 371.04 | 61.0% | 8.7% | 326.91 | 56.8% | 6.8% |
| 30Δ | 365.44 | 59.6% | 7.4% | 332.05 | 54.2% | 5.7% |
| 35Δ | 359.92 | 57.7% | 6.1% | 336.10 | 53.3% | 4.9% |
| 40Δ | 355.87 | 59.0% | 5.5% | 340.14 | 52.4% | 4.1% |
| 45Δ | 351.83 | 60.3% | 4.8% | 343.74 | 52.6% | 3.6% |
| 50Δ | 347.75 | 60.4% | 4.2% | 347.35 | 52.7% | 3.1% |
| 55Δ | 343.66 | 59.6% | 3.5% | 350.99 | 52.8% | 2.6% |
| 60Δ | 339.50 | 59.2% | 2.9% | 354.76 | 52.5% | 2.2% |
| 65Δ | 334.84 | 61.2% | 2.5% | 358.52 | 52.3% | 1.8% |
| 70Δ | 330.19 | 63.2% | 2.1% | 362.69 | 52.0% | 1.4% |
| 75Δ | 324.43 | 65.3% | 1.7% | 367.11 | 51.8% | 1.1% |
| 80Δ | 318.34 | 67.1% | 1.3% | 372.05 | 51.7% | 0.8% |
20Δ
- Pseudo strike
- 376.79
- IV
- 60.3%
- B/E move
- 10.0%
- Pseudo strike
- 320.66
- IV
- 61.1%
- B/E move
- 8.4%
25Δ
- Pseudo strike
- 371.04
- IV
- 61.0%
- B/E move
- 8.7%
- Pseudo strike
- 326.91
- IV
- 56.8%
- B/E move
- 6.8%
30Δ
- Pseudo strike
- 365.44
- IV
- 59.6%
- B/E move
- 7.4%
- Pseudo strike
- 332.05
- IV
- 54.2%
- B/E move
- 5.7%
35Δ
- Pseudo strike
- 359.92
- IV
- 57.7%
- B/E move
- 6.1%
- Pseudo strike
- 336.10
- IV
- 53.3%
- B/E move
- 4.9%
40Δ
- Pseudo strike
- 355.87
- IV
- 59.0%
- B/E move
- 5.5%
- Pseudo strike
- 340.14
- IV
- 52.4%
- B/E move
- 4.1%
45Δ
- Pseudo strike
- 351.83
- IV
- 60.3%
- B/E move
- 4.8%
- Pseudo strike
- 343.74
- IV
- 52.6%
- B/E move
- 3.6%
50Δ
- Pseudo strike
- 347.75
- IV
- 60.4%
- B/E move
- 4.2%
- Pseudo strike
- 347.35
- IV
- 52.7%
- B/E move
- 3.1%
55Δ
- Pseudo strike
- 343.66
- IV
- 59.6%
- B/E move
- 3.5%
- Pseudo strike
- 350.99
- IV
- 52.8%
- B/E move
- 2.6%
60Δ
- Pseudo strike
- 339.50
- IV
- 59.2%
- B/E move
- 2.9%
- Pseudo strike
- 354.76
- IV
- 52.5%
- B/E move
- 2.2%
65Δ
- Pseudo strike
- 334.84
- IV
- 61.2%
- B/E move
- 2.5%
- Pseudo strike
- 358.52
- IV
- 52.3%
- B/E move
- 1.8%
70Δ
- Pseudo strike
- 330.19
- IV
- 63.2%
- B/E move
- 2.1%
- Pseudo strike
- 362.69
- IV
- 52.0%
- B/E move
- 1.4%
75Δ
- Pseudo strike
- 324.43
- IV
- 65.3%
- B/E move
- 1.7%
- Pseudo strike
- 367.11
- IV
- 51.8%
- B/E move
- 1.1%
80Δ
- Pseudo strike
- 318.34
- IV
- 67.1%
- B/E move
- 1.3%
- Pseudo strike
- 372.05
- IV
- 51.7%
- B/E move
- 0.8%
Options history
Table
| Date | IV (%) |
|---|---|
| 45.47% | |
| 43.80% | |
| 47.02% | |
| 46.60% | |
| 48.29% | |
| 51.22% | |
| 47.18% | |
| 47.27% | |
| 46.34% | |
| 46.57% | |
| 46.25% | |
| 45.64% | |
| 46.30% | |
| 47.64% | |
| 46.55% | |
| 45.99% | |
| 46.28% | |
| 48.57% | |
| 48.29% | |
| 48.96% | |
| 46.73% | |
| 50.08% | |
| 49.42% | |
| 55.47% | |
| 54.53% | |
| 49.68% | |
| 50.49% | |
| 49.42% | |
| 50.23% | |
| 49.19% | |
| 48.83% | |
| 49.08% | |
| 48.71% | |
| 48.62% | |
| 48.23% | |
| 47.93% | |
| 47.96% | |
| 50.41% | |
| 50.85% | |
| 50.84% | |
| 49.35% | |
| 52.53% | |
| 52.36% | |
| 55.28% | |
| 56.81% | |
| 54.52% | |
| 53.76% | |
| 54.49% | |
| 53.23% | |
| 54.62% | |
| 55.36% | |
| 56.69% | |
| 55.59% | |
| 55.69% | |
| 56.21% | |
| 60.02% |
Diagnostics & Research
CSTL
Castle Biosciences Inc. is a pioneering diagnostics firm that enhances patient care through advanced gene-expression profiling tests, particularly within the skin cancer sector,…
More →DGX
Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains…
More →DHR
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional,…
More →FLGT
Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in…
More →GH
Guardant Health, Inc., a precision oncology company, offers blood testing, data sets, and testing in the United States and internationally. The company is headquartered in Redwood…
More →GRAL
Description unavailable
More →